BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35834073)

  • 21. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
    Kah J; Wüstenberg A; Keller AD; Sirma H; Montalbano R; Ocker M; Volz T; Dandri M; Tiegs G; Sass G
    Oncol Rep; 2012 Sep; 28(3):1077-83. PubMed ID: 22710979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
    Simon M; Mesmar F; Helguero L; Williams C
    PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer.
    Sun Q; Arnold RS; Sun CQ; Petros JA
    Prostate; 2015 Dec; 75(16):1916-25. PubMed ID: 26383260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
    Kou X; Jiang X; Liu H; Wang X; Sun F; Han J; Fan J; Feng G; Lin Z; Jiang L; Yang Y
    Cancer Sci; 2018 Oct; 109(10):3272-3284. PubMed ID: 30039622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade.
    Chang HL; Chen CY; Hsu YF; Kuo WS; Ou G; Chiu PT; Huang YH; Hsu MJ
    Biochim Biophys Acta; 2013 Aug; 1830(8):4053-64. PubMed ID: 23583370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
    Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
    Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.
    Kou X; Yang Y; Jiang X; Liu H; Sun F; Wang X; Liu L; Liu H; Lin Z; Jiang L
    Eur J Pharmacol; 2017 Oct; 813():161-171. PubMed ID: 28826913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simvastatin induces caspase-dependent apoptosis and activates P53 in OCM-1 cells.
    Wang Y; Xu SL; Wu YZ; Zhao MS; Xu WJ; Yang HY; Li YX
    Exp Eye Res; 2013 Aug; 113():128-34. PubMed ID: 23727160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
    Pääjärvi G; Roudier E; Crisby M; Högberg J; Stenius U
    FASEB J; 2005 Mar; 19(3):476-8. PubMed ID: 15625077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell cycle arrest and apoptosis in triple-negative breast cancer cells with mutant p53.
    Sutton KM; Greenshields AL; Hoskin DW
    Nutr Cancer; 2014; 66(3):408-18. PubMed ID: 24579801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study.
    Wang H; Wang Z; Wang Z; Li X; Li Y; Yan N; Wu L; Liang Y; Wu J; Song H; Qu Q; Huang J; Chang C; Shen K; Chen X; Lu M
    Front Med; 2024 Apr; 18(2):357-374. PubMed ID: 38157193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression.
    Huang X; Ma J; Xu J; Su Q; Zhao J
    Mol Med Rep; 2015 Mar; 11(3):2334-40. PubMed ID: 25412322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis.
    Chou CW; Lin CH; Hsiao TH; Lo CC; Hsieh CY; Huang CC; Sher YP
    Sci Rep; 2019 Dec; 9(1):20403. PubMed ID: 31892709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins decrease the expression of c-Myc protein in cancer cell lines.
    Rao PS; Rao US
    Mol Cell Biochem; 2021 Feb; 476(2):743-755. PubMed ID: 33070276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins Inhibit Toll-Like Receptor 4-Mediated Growth of Human Esophageal Adenocarcinoma Cells.
    Gergen AK; Kohtz PD; Halpern AL; White AM; Meng X; Fullerton DA; Weyant MJ
    J Surg Res; 2021 Apr; 260():436-447. PubMed ID: 33272595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53.
    Chan KC; Wang CJ; Ho HH; Chen HM; Huang CN
    Pharmacol Res; 2008; 58(3-4):247-56. PubMed ID: 18804536
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Terzi H; Altun A; Şencan M
    Indian J Med Res; 2019 Dec; 150(6):630-634. PubMed ID: 32048627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.